Bellevue Healthcare Trust PLC (LSE:BBH) co-portfolio manager Paul Major spoke with Proactive's Stephen Gunnion about the implications of Donald Trump and the Republicans' victory in the recent US election on the healthcare sector.
Major explained that while initial reactions may predict challenges due to inflationary pressures, a more nuanced analysis points to potential benefits, particularly in M&A activity. He noted, “The licensing and acquisition of new products is the lifeblood of big pharma,” emphasising that a reduction in antitrust actions could spur large-scale mergers and acquisitions, catalysing interest in the biotech sector.
Major highlighted that despite inflation concerns, healthcare fundamentals remain strong due to consistent demand and demographic trends.